N. Gopalakrishna Iyer, Luc G. T. Morris, R. Michael Tuttle, Ashok R. Shaha and Ian Ganly Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy Cancer 117
Version of Record online: 22 MAR 2011 | DOI: 10.1002/cncr.26070
Despite the lack of evidence for any benefit from radioactive iodine (RAI) ablation in patients with low-risk (T1N0), differentiated thyroid cancer, statistics from the Surveillance, Epidemiology, and End Results database indicate that its use has increased from 3.3% to 38.1% in the last 3 decades. The use of RAI is associated with a significantly higher incidence of second primary malignancies, providing a strong rationale for limiting its use in this patient population.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field